Sanofi’s Zerhouni on Drug Pricing Under Trump

The video discusses the complexities of drug pricing, emphasizing the need for prices that reflect the value provided by innovative drugs. It highlights systemic issues in the pharmaceutical industry, the role of government in health policy, and the debate between intellectual property rights and public health. The video also covers the potential impact of new FDA leadership and the collaboration between Sanofi and Actelion in the rare disease sector.

What does the speaker suggest about the role of generics in drug pricing?

What is the speaker's opinion on the potential appointment of Jim O'Neill as FDA Commissioner?

How does the speaker describe the current state of intellectual property in relation to drug development?